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Abstract
Objective: The integrity and function of the gastrointestinal system is important in disease prevention and
management. This study aims to describe the management methods used by Australian adults with suspected
increased intestinal permeability (IP) and the association with subjective wellbeing (SWB) and health-related
quality of life (HRQoL).
Design and Setting: Cross-sectional survey of Australian adults diagnosed with IP or have suspected (un-
diagnosed) IP.
Outcome Measures: Questionnaire items investigating demographic characteristics, self-reported outcome of
IP and treatment methods used to manage IP. Participants’ HRQoL and SWB according to the 20-Item Short
Form Health Survey (SF-20) and Personal Wellbeing Index-Adult (PWI-A) scale, respectively.
Results: Participants (n = 589) frequently used dietary products (87.9%), dietary supplements (72.9%) and
lifestyle therapies (54.6%) for managing IP. Participants had lower (i.e., worse) mean SWB scores for all
domains compared to the Australian population (p < 0.001). The number of days IP reported to affect daily
living was negatively correlated with SWB and HRQoL (p < 0.001). Participants that reported an improvement
in their IP in the previous 12 months were more likely to be treated by a healthcare practitioner (OR = 2.04,
p = 0.015), use dietary supplements (OR = 2.66, p = 0.003), participate in vigorous exercise (OR = 2.99,
p < 0.001) and employ vagus nerve stimulation (OR = 3.10, p = 0.010). Conversely, they were less likely to
consume gluten (OR = 0.35, p < 0.001) or use nonsteroidal anti-inflammatory drugs (OR = 0.35, p = 0.022). Self-
reported improvement of IP (b= 10.70, p < 0.001) and use of dietary products (b= 12.12, p = 0.008) were
predictors of a higher level of SWB.
Conclusions: Altered IP may pose a greater health burden than previously thought, with poor SWB and
HRQoL reported in Australian adults with self-reported IP. Our results highlight the potential clinical relevance
and consequence of altered IP, providing the first indication of a possible relationship between altered IP and
both SWB and HRQoL.
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Introduction
The health of the gastrointestinal system has become atarget of interest for disease prevention.1 One specific
gastrointestinal target area is the integrity of the intestinal
barrier of the small intestine. During increased intestinal
permeability (IP), the tight junction proteins between the
cells of the small intestine disassemble in response to the
protein zonulin.2 The single layer of epithelium cells in the
small intestine contributes to the biochemical and physical
barrier to the array of foreign pathogens, allergens, and other
toxins.3 The prevalence of altered IP has been suggested to be
10%–87% in health conditions with a known association.4
During a loss of intestinal integrity, a cascade of reactions
contributes to systemic symptoms and disease progression
with the mitigation of zonulin that is suggested to inhibit or
reduce disease onset.5,6 Although no defined symptoms of IP
have been identified,5,7 a range of risk factors are known to be
associated with altered IP.5 The clinical risk factors associ-
ated with IP provide a potential platform for treatment in-
terventions and areas for further investigation.
The management of altered IP may involve the use or
avoidance of dietary products (e.g., increasing dietary fiber,
avoidance of gluten and alcohol), lifestyle therapies (e.g.,
stress management, vagus nerve stimulation), dietary sup-
plements (e.g., vitamin A, probiotics, Curcuma longa, fish
oil), and medication evaluation (e.g., avoidance of nonste-
roidal anti-inflammatory drugs [NSAIDs] and antibiotics or
the use of larazotide acetate).6,8–10 These methods are pro-
posed to have multiple direct and indirect modulatory ac-
tions that regulate intestinal integrity.8,9 Many of the
treatments used by practitioners for the management of IP
have previously been shown to align with preclinical re-
search.9 Although these treatment methods are frequently
used in clinical practice, there still remains limited evidence
for the effective management of altered IP. A broad health
services research-based study may help identify the poten-
tial areas for further clinical trials.11
The clinical relevance and consequence of altered IP in
clinical practice have recently been questioned,12 despite
identified associations between IP and a wide range of health
conditions.4 Questions regarding the clinical relevance and
consequence of altered IP may stem from a low level of
awareness and understanding regarding the potential effect of
altered IP on individuals, especially their quality of life (QoL)
and subjective well-being (SWB). QoL is an important con-
tributor to overall disease burden alongside financial burden,
mortality, and morbidity.13,14 Health-related quality of life
(HRQoL) is a multidimensional concept that measures the
impact of health status on QoL and includes mental, physical,
emotional, and social functioning.15 In addition to HRQoL, a
person’s SWB—also referred to as life satisfaction—can be a
determinant in quantifying the clinical relevance and conse-
quence of ill health. The SWB is a multidimensional construct
comprising cognitive and affective components that reflect an
individual’s appraisal of their satisfaction with their life.16,17
Understanding the SWB of individuals with particular health
conditions may help identify populations with greater mor-
tality risk18 and guide the development of targeted supportive
interventions.
The impact of altered IP on individuals’ HRQoL and
SWB, and the treatments used in the management of IP,
remains under-examined. As such, this study has two pri-
mary aims: to describe the SWB and HRQoL of Australian
adults with suspected IP and to explore the treatment
methods used by this population group.
Materials and Methods
Study design and setting
A cross-sectional study design using an online self-
reported survey was deployed. Approval for the study was
obtained from the Human Research Ethics Committees
(HREC) of the University of Technology Sydney (ETH19-
4012). The health-seeking behavior, views, and preferences
of this study cohort have previously been published.19
Participants and recruitment
Participants were recruited via social media platforms and
a purpose-built webpage, with snowball sampling methods
used. The authors shared the survey on their social media
and known Facebook groups, such as Leaky Gut and Mi-
crobiome Support Group Australia. The survey was open for
2 months between September 2019 and November 2019.
Eligibility questions asked participants whether they believe
they have IP (self-diagnosed) or have been diagnosed with
IP. To participate in the study, participants were also re-
quired to be 18 years of age or older, living in Australia, and
have Internet access. The target population, although broad,
represents an under-examined population group; as such,
this study was designed to capture people with suspected IP
or confirmed IP. As IP is suggested to be underdiagnosed,
including participants who self-diagnose IP best reflects the
target population and the patients who present to clinical
practice for the treatment of IP.7 Survey responders with
incomplete demographic characteristics, accounting for
<5% of total data, were excluded from analysis.
Survey and data collection
The online survey administered through the online plat-
form SurveyGizmo utilized questionnaire items previously
developed to investigate IP in Australia.7,9 The survey was
pilot tested by four lay individuals to assess language clar-
ity, with the required corrections made. The survey included
four main domains: demographic characteristics, treatment
methods for altered IP, SWB, and HRQoL.
Demographic characteristics
The participants were asked about their gender, age, height,
and weight from which body mass index (BMI) was calculated
and categorized to underweight, healthy weight, overweight,
and obese.20 The participants were further asked about their
country of birth, the state or territory where they reside, and
whether this was in an urban, rural, or remote location. The
participant’s income manageability was determined by how
well they manage their household income, categorized as
‘‘difficult all the time,’’ ‘‘difficult some of the time,’’ ‘‘not too
bad,’’ or ‘‘easy.’’
Self-reported outcome of increased IP
Two questions were asked to explore the potential se-
verity of IP. First, participants were asked whether they
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believed their IP has become ‘‘better,’’ ‘‘worse,’’ or ‘‘no
change’’ over the previous 12 months. Participants were
then asked how many days a week does their IP affect their
daily living with the option of 0–7 days.
Treatment of increased IP
A selection of survey items involving dietary products,
lifestyle therapies, dietary supplements, and medications
that may either improve or exacerbate IP along with open-
ended questions were used to document how frequently
these methods were used. The frequency of use for dietary
products, lifestyle therapies, dietary supplements, and
medications were measured by using a six-point scale
(‘‘never,’’ ‘‘less than once a month,’’ ‘‘1–3 times a month,’’
‘‘once a week,’’ ‘‘2–6 times a week,’’ ‘‘every day’’). These
treatment methods were further explored in relation to the
person who prescribed the treatment, mainly the qualifica-
tion of the practitioner or whether the treatment was self-
prescribed.
Subjective well-being
Participants’ SWB was measured by using the Personal
Well-being Index—Adult (PWI-A) scale—an instrument
validated in Australian population samples.21 The PWI scale
consisted of seven domains of satisfaction: standard of living,
personal health, achieving in life, personal relationships,
personal safety, community-connectedness, and future secu-
rity.21 The PWI scoring system of each domain is reported on a
0–10 scale, with 0 representing no satisfaction at all and 10
being completely satisfied.
Quality of life
The 20-Item Short Form Health Survey (SF-20) was used
to measure participants’ HRQoL.22 The SF-20 assesses six
health domains: physical functioning (six questions), role
functioning (two questions), social functioning (one ques-
tion), mental health (five questions), current health percep-
tions (five questions), and bodily pain (one question).
Statistical analyses
Data were exported to STATA 16 for statistical analyses.
Variables were reported as means, standard deviations
(SDs), 95% confidence intervals (CIs), or frequencies and
percentages, where appropriate. Chi-square analysis was
used to examine the association between two categorical
variables, with Student’s t-tests used for continuous vari-
ables across a binary variable. Analysis of variance was used
to measure the difference between a continuous variable
across a categorical variable. Spearman’s correlation anal-
ysis was used to measure the correlation between the
number of days that IP affects daily living, SWB, and
HRQoL. Logistic and linear regression models were used
when considering multiple factors. Variables associated
with SWB, HRQoL, or the number of days that IP affects
daily living—with a bivariate p-value <0.2523—were en-
tered into the respective multivariate logistic or linear re-
gression models, to adjust for potential confounders.
A stepwise backward elimination process was then used to
identify the most important independent predictors.
For analysis, participants’ use of dietary products, lifestyle
therapies, dietary supplements, and medications were
grouped as frequently (‘‘once a week,’’ ‘‘2–6 times a week,’’
and ‘‘every day’’) and infrequently (‘‘less than once a
month,’’ ‘‘1–3 times a month,’’ and ‘‘never’’). Although
participants were able to select either ‘‘exacerbation,’’ ‘‘im-
provement,’’ or ‘‘no change’’ for the self-reported outcome of
IP in the previous 12 months, only data from exacerbation
and improvement were used during analysis. Practitioners
were categorized as ‘‘medical practitioners’’ (integrative
medicine practitioners, general practitioners, and gastroen-
terologists) and ‘‘healthcare practitioners’’ (all practitioners).
Analysis and interpretation of the data collected from the
PWI-A scale were undertaken according to a previously
published work.24 Participants who answered consistently 0/
10 or 10/10 across all PWI domains were excluded due to a
risk of response bias.24 For analysis, the raw scores were
transformed to a 0–100 scale. The combined mean score from
the seven domains represents the participants’ overall SWB.
A two-sample t-test was used to compare the normative mean
of the surveyed sample and the Australian population.25
The analysis and interpretation of the SF-20 were un-
dertaken according to a previously published work.22 For
analysis, the SF-20 item scores were transformed to a scale of
0 to 100, with 0 representing the worst perceived health-
related outcome. Item scores for each domain were combined
and averaged to produce the final domain score (0–100).
Higher scores reflect better perceived health-related out-




There were 982 responses to the survey, of which 393
responses were excluded as the initial eligibility questions
were not answered and thereby classified as not meeting the
eligibility criteria; this left a total of 589 participants. Most
participants were female (93%), with a mean age of 45.0
years (SD = 12.1; range 18–82) and a mean BMI of 27.0
(SD = 6.9). Participants’ BMI were classified as healthy
weight (46.1%), obese (26.9%), overweight (23.8%), and
underweight (3.3%). Most participants were born in Australia
(81.0%) and resided in New South Wales (29.7%), Queens-
land (27.3%), Victoria (17.5%), or Western Australia
(10.7%), in an urban (70.6%), rural (27.3%), or remote area
(2.0%). Most participants described their income manage-
ability as ‘‘easy or not too bad’’ (46.5%), followed by ‘‘dif-
ficult some of the time’’ (32.3%) or ‘‘difficult all the time’’
(21.2%). The major health concerns reported by participants
were IP (n = 300, 50.9%), autoimmune conditions (n = 40,
6.8%), Hashimoto’s thyroiditis (n = 28, 4.8%), gastrointestinal
issues (n = 24, 4.1%), chronic fatigue syndrome (n = 21,
3.6%), and rheumatoid arthritis (n = 18, 3.1%).
Practitioners consulted with, and treatments
used, for managing increased IP
Participants most frequently reported using dietary
products (87.9%), dietary supplements (72.9%), and life-
style therapies (54.6%) for the management of IP. Medica-
tions were infrequently used by participants for the
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treatment of IP (8.5%). Self-prescribing of treatment meth-
ods for the management of IP was most frequently reported
(59.6%), followed by prescription from a naturopath
(43.1%), integrative medicine practitioner (19.3%), general
practitioner (16.8%), and nutritionist (12.4%) (Table 1).
Both dietary products (53.0%) and lifestyle therapies
(33.8%) were frequently self-prescribed. However, dietary
supplements and medications were most frequently pre-
scribed by a naturopath (37.3%) and general practitioner
(4.4%), respectively.
Self-reported outcome of increased IP
In the previous 12 months, more participants reported that
their IP had improved (55.8%). Half of the participants
(50.0%) reported that IP affected their daily living 7 days a
week. Further, participants who described an improvement
in their IP during the previous 12 months reported that IP
affected their daily life 4.0 days a week (95% CI: 3.6–4.4);
however, participants who described exacerbation of their IP
in the previous 12 months reported that IP affected their
daily life 6.0 days a week (95% CI: 5.7–6.3; p < 0.001).
A self-reported improvement in IP was associated with
participants who were treated by a practitioner compared with
those who were not treated by a practitioner (76.1% vs.
23.9%; p < 0.001). Participants who reported that their IP had
worsened in the previous 12 months had a significantly higher
mean BMI compared with those who reported an improve-
ment in their IP in the past 12 months (28.4 vs. 25.5;
p < 0.001). Multivariate logistic regression analysis found that
the use of NSAIDs (b= 1.08; 95% CI: 0.17–1.98; p = 0.021),
lifestyle therapies (b= 1.08; 95% CI: 0.46–1.70; p = 0.001),
and Saccharomyces boulardii (b= 1.56; 95% CI: 0.46–2.67;
p = 0.006) were predictors of a greater number of days each
week that IP was reported to affect daily living. However,
reporting an improvement of their IP in the previous 12
months (b= -1.78; 95% CI: -2.39 to -1.17; p < 0.001), and
infrequently (b= -0.90; 95% CI: -1.64 to -0.16; p = 0.017) or
frequently (b= -0.82; 95% CI: -1.49 to -0.16; p = 0.016)
practicing yoga were found to be predictors for a fewer
number of days affecting daily living each week.
Table 1. Frequency of Treatment Methods Used for Increased Intestinal Permeability (n = 483)
Who prescribed treatment
Treatment methods used for increased IPa
Total Dietary products Lifestyle therapies Dietary supplements Medications
n % n % n % n % n %
Self-prescribed 288 59.6 256 53.0 163 33.8 156 32.3 11 2.3
Naturopath 208 43.1 175 36.2 104 21.5 180 37.3 0 0.0
Integrative medicine practitioner 93 19.3 77 15.9 47 9.7 84 17.4 11 2.3
General practitioner 81 16.8 60 12.4 30 6.2 34 7.0 21 4.4
Nutritionist 60 12.4 57 11.8 28 5.8 47 9.7 0 0.0
Dietitian 37 7.7 34 7.0 12 2.5 15 3.1 0 0.0
Chinese medicine practitioner 28 5.8 17 3.5 12 2.5 24 5.0 0 0.0
Chiropractor 28 5.8 16 3.3 22 4.6 15 3.1 0 0.0
Acupuncturist 24 5.0 12 2.5 11 2.3 18 3.7 0 0.0
Herbalist 24 5.0 15 3.1 14 2.9 22 4.6 0 0.0
Gastroenterologist 20 4.1 13 2.7 5 1.0 8 1.7 3 0.6
Kinesiologist 20 4.1 14 2.9 12 2.5 12 2.5 0 0.0
Ayurvedic practitioner 12 2.5 10 2.1 5 1.0 9 1.9 0 0.0
Homeopath 12 2.5 8 1.7 7 1.5 9 1.9 0 0.0
Osteopath 7 1.5 6 1.2 5 1.0 5 1.0 0 0.0
Pharmacist 5 1.0 1 0.2 1 0.2 5 1.0 1 0.2
Nurse 4 0.8 4 0.8 2 0.4 2 0.4 2 0.4
Nurse practitioner 2 0.4 2 0.4 2 0.4 1 0.2 1 0.2
aParticipants were able to select multiple treatment methods.
IP, intestinal permeability.
Table 2. Treatment-Related Characteristics
and the Improvement of Increased Intestinal
Permeability in the Previous 12 Months (n = 287)
Characteristics Odds ratio (95% CI) p
Treating person
Self 1.00
Health care practitioner 2.04 (1.15–3.61) 0.015
Gluten
Never 1.00
Frequently 0.35 (0.20–0.61) <0.001
Vigorous exercise
Never 1.00
Frequently 2.99 (1.61–5.53) <0.001
Vagus nerve stimulation
Never 1.00
Frequently 3.10 (1.31–7.31) 0.010
NSAIDs
Never 1.00
Infrequently 0.48 (0.26–0.86) 0.014
Frequently 0.35 (0.15–0.86) 0.022
Using dietary supplements
No 1.00
Yes 2.66 (1.40–5.05) 0.003
NSAIDs, nonsteroidal anti-inflammatory drugs.
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Treatment-related characteristics of increased
IP improvement
Participants who reported an improvement in their IP in the
previous 12 months were more likely to be treated by a health
care practitioner (OR = 2.04, p = 0.015), use dietary supple-
ments (OR = 2.66, p = 0.003), participate in vigorous exercise
(OR = 2.99, p < 0.001), and employ vagus nerve stimulation
(OR = 3.10, p = 0.010) (Table 2). Further, participants who
reported an improvement in their IP during the previous 12
months were also less likely to consume gluten (OR = 0.35,
p < 0.001) or use NSAIDs (OR = 0.35, p = 0.022).
Associations between common dietary products,
lifestyle therapies, medications, and the self-reported
outcome of increased IP
Participants who reported frequently consuming organic
foods ( p < 0.001), fermented foods ( p = 0.004), bone broth
( p = 0.001), collagen ( p < 0.001), or apple cider vinegar
( p = 0.026) described an improvement in their IP in the
previous 12 months compared with those who infrequently
consumed these dietary products (Table 3). Further, partic-
ipants who reported infrequently consuming dairy products
( p = 0.012), refined sugar ( p < 0.001), or gluten-containing
products ( p < 0.001) described an improvement in their IP in
the previous 12 months compared with participants who
reported frequently consuming these dietary products. Par-
ticipants who reported frequently practicing breathing ex-
ercises ( p < 0.001), stress management ( p < 0.001),
meditation ( p = 0.037), vigorous exercise ( p < 0.001), yoga
( p = 0.001), or vagus nerve stimulation ( p < 0.001) more
commonly described an improvement in their IP in the
previous 12 months compared with participants who infre-
quently reported practicing these lifestyle therapies. Parti-
cipants who infrequently used NSAIDs ( p = 0.001) more
commonly described an improvement in their IP in the
previous 12 months compared with participants who fre-
quently used NSAIDs.
Frequency of dietary supplements use
for the treatment of increased IP
The most frequently used dietary supplements for the
management of IP were probiotics (36.1%), herbal mix-
tures (26.6%), prebiotics (21.7%), zinc (21.7%), glutamine
(19.4%), magnesium (19.1%), and vitamin D (15.6%)
(Table 4). Dietary supplements were most frequently used
by participants who described an improvement in their IP
during the previous 12 months compared with those who
described exacerbation of their IP (63.3%–86.8% vs.
13.2%–36.7%). Participants frequently reported using di-
etary supplements as prescribed by a practitioner rather
than self-prescribed (66.7%–87.8% vs. 12.2%–33.3%)
(Table 4). There was a statistically significant association
between the use of dietary supplements and the self-
reported outcome of IP. Specifically, participants who used
zinc ( p = 0.05), glutamine ( p = 0.02), magnesium
( p = 0.006), vitamin C ( p = 0.03), or vitamin B complex
( p = 0.001) described an improvement in their IP during
the previous 12 months.
Table 3. Associations Between Common Dietary
Products, Lifestyle Therapies, Medications,
and the Self-Reported Outcome of Intestinal
Permeability in the Previous 12 Months (n = 483)
Self-reported outcome
of increased IP
in the previous 12 months
Total Exacerbation Improvement
n % % % p
Dietary products
Red meat
Frequently 357 74.2 44.6 55.4 0.909
Infrequently 124 25.8 43.9 56.1
Organic foods
Frequently 331 69.4 37.6 62.4 <0.001
Infrequently 146 30.6 58.8 41.2
Dairy
Frequently 279 57.9 50.6 49.4 0.012
Infrequently 203 42.1 36.4 63.6
Refined sugar
Frequently 239 49.8 59.6 40.4 <0.001
Infrequently 241 50.2 30.8 69.2
Fermented foods
Frequently 220 46.2 36.1 63.9 0.004
Infrequently 256 53.8 52.3 47.7
Gluten
Frequently 213 44.4 64.1 35.9 <0.001
Infrequently 267 55.6 30.3 69.7
Apple cider vinegar
Frequently 179 37.3 36.1 63.9 0.026
Infrequently 301 62.7 49.0 51.0
Bone broth
Frequently 173 36.1 32.5 67.5 0.001
Infrequently 306 63.9 51.3 48.7
Collagen
Frequently 166 35.0 31.1 68.9 <0.001
Infrequently 308 65.0 51.3 48.7
Alcohol
Frequently 148 30.9 47.4 52.6 0.472
Infrequently 331 69.1 43.1 56.9
Lifestyle therapies
Breathing exercises
Frequently 212 45.5 34.4 65.6 <0.001
Infrequently 254 54.5 55.3 44.7
Stress management
Frequently 210 45.2 34.0 66.0 <0.001
Infrequently 255 54.8 57.1 42.9
Meditation
Frequently 191 40.8 38.7 61.3 0.037
Infrequently 277 59.2 50.6 49.4
Vigorous exercise
Frequently 146 30.9 28.4 71.6 <0.001
Infrequently 327 69.1 51.4 48.6
Yoga
Frequently 133 28.5 31.3 68.8 0.001
Infrequently 333 71.5 50.7 49.3
Vagus nerve stimulation
Frequently 61 13.3 20.5 79.6 <0.001
Infrequently 399 86.7 48.8 51.2
Medications
NSAIDs
Frequently 63 13.4 69.2 30.8 0.001
Infrequently 407 86.6 40.2 59.8
Prednisone
Frequently 16 3.5 41.7 58.3 0.827
Infrequently 447 96.5 44.9 55.1
Methotrexate
Frequently 11 2.4 57.1 42.9 0.704
Infrequently 448 97.6 43.9 56.1
Antibiotics
Frequently 6 1.3 60.0 40.0 0.657
Infrequently 460 98.7 43.6 56.4
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Subjective well-being and HRQoL
There was a statistically significant difference in overall
SWB and each domain of SWB between Australian adults
with suspected IP and the Australian population ( p < 0.001).
Specifically, Australian adults with suspected IP had lower
(i.e., worse) average scores for all domains compared with
the Australian population. A t-test showed that partici-
pants who described exacerbation of their IP had a worse
(M = 54.7, SD = 20.3) SWB than those reporting an im-
provement (M = 66.1, SD = 19.6) in their IP ( p < 0.001).
Spearman’s correlation analysis revealed that the number of
days that IP affects daily life had a negative correlation with
SWB and HRQoL ( p < 0.001). Results for correlation ana-
lyses are summarized in Table 5.
Subjective well-being and common dietary products,
lifestyle therapies, and medications
Pairwise comparison found a statistically significant dif-
ference between the overall SWB of participants, and the
frequency of common dietary products, lifestyle therapies,
and medication use. Participants who used any form of
Table 4. Associations Between Dietary Supplements and Self-reported Outcome of Increased Intestinal
Permeability in the Previous 12 Months and Percentage for Person Prescribing Each Treatment (n = 346)
Dietary supplements
Self-reported outcome of IP in the previous 12 months Person who prescribed treatment
Total Exacerbation Improvement Self-prescribed Practitioner prescribed
n % % % p % %
Probiotic 125 36.1 33.3 66.7 0.483 27.0 73.0
Herbal mixtures 92 26.6 28.4 71.6 0.111 26.4 73.6
Prebiotic 75 21.7 27.6 72.4 0.113 23.0 77.0
Zinc 75 21.7 25.4 74.6 0.05 20.0 80.0
Glutamine 67 19.4 22.5 77.6 0.02 25.8 74.2
Magnesium 66 19.1 19.2 80.9 0.006 29.2 70.8
Vitamin D 54 15.6 35.9 64.1 0.956 30.2 69.8
Vitamin C 50 14.5 18.8 81.3 0.03 20.4 79.6
Vitamin B complex 49 14.2 13.2 86.8 0.001 12.2 87.8
Omega 3 48 13.9 33.3 66.7 0.689 33.3 66.7
Curcuma longa 42 12.1 23.3 76.7 0.114 30.9 69.1
Slippery elm 41 11.9 28.6 71.4 0.366 17.1 82.9
Aloe vera 39 11.3 24.1 75.9 0.146 23.7 76.3
Digestive enzyme 37 10.7 36.7 63.3 0.963 13.5 86.5
Multivitamin 37 10.7 20.7 79.3 0.062 24.3 75.7
Amino acid mix 31 9.0 32.0 68.0 0.637 29.0 71.0
Saccharomyces
boulardii
21 6.1 18.8 81.3 0.131 14.3 85.7
Vitamin A 19 5.5 33.3 66.7 0.806 26.3 73.7
Table 5. Spearman’s Correlation Between Quality of Life and Subjective Well-being with the Number
of Days Increased Intestinal Permeability Affects Daily Life Each Week (0–7 Days)
n Mean SD Correlation coefficient p
Subjective well-being
Personal well-being index 422 60.3 20.3 -0.402 <0.001
Standard of living 422 65.0 25.5 -0.313 <0.001
Health 422 43.4 24.6 -0.453 <0.001
Achieving in life 422 56.1 25.6 -0.377 <0.001
Personal relationship 422 64.2 26.3 -0.261 <0.001
Personal safety 422 75.3 24.3 -0.193 <0.001
Community connectedness 422 59.3 27.2 -0.277 <0.001
Future security 422 58.8 27.9 -0.273 <0.001
Quality of life
Physical functioning 423 61.9 33.8 -0.275 <0.001
Role functioning 423 57.3 42.5 -0.335 <0.001
Social functioning 423 60.5 32.3 -0.388 <0.001
Mental health 423 55.0 21.6 -0.294 <0.001
Health perception 423 37.2 28.5 -0.474 <0.001
Bodily pain 423 50.4 25.1 0.316 <0.001
Score ranges from 0 to 100. A high score indicates better health except for pain, where a high score indicates more pain.
SD, standard deviation.





















































































































































































































































































































































































































































































































































































































































































































































































































































dietary products (M = 61.0, SD = 20.4) for the treatment of
IP were found to have better SWB compared with those
who never used dietary products (M = 54.6, SD = 18.7)
( p = 0.023). Further, participants who never consumed
gluten-containing foods (M = 65.2, SD = 21.5) were found to
have better SWB compared with participants who frequently
consumed gluten (M = 59.1, SD = 19.8) ( p = 0.037). How-
ever, participants who frequently consumed alcohol (M =
64.9, SD = 18.7) were found to have better SWB compared
with those who never consumed alcohol (M = 54.0,
SD = 22.4) ( p < 0.001). Further, participants who frequently
practiced breathing exercises (M = 63.0, SD = 19.4; M = 56.2,
SD = 21.5) ( p = 0.014), stress management (M = 62.4,
SD = 19.0; M = 56.1, SD = 23.7) ( p = 0.036), vigorous exer-
cise (M = 66.2, SD = 18.4; M = 55.3, SD = 20.9) ( p < 0.001),
or yoga (M = 68.0, SD = 17.0; M = 56.0, SD = 20.9)
( p < 0.001) were found to have better SWB compared with
participants who never participated in these lifestyle thera-
pies. Lastly, participants who never used NSAIDs (M = 62.5,
SD = 21.5) were found to have better SWB compared with
those who frequently used them (M = 54.3, SD = 19.5)
( p = 0.026).
Multiple regression predicting SWB and HRQoL
Seven regression models predicting overall SWB, and
each HRQoL domain were undertaken. The results of these
regression models found that the outcome of IP in the pre-
vious 12 months, BMI, the treating person, and the use of
dietary products and lifestyle therapies were all statistically
significant predictors of overall SWB and each HRQoL
domain (Table 6). Specifically, improvement of IP
(b = 10.70, p < 0.001) and using dietary products (b = 12.12,
p = 0.008) were predictors of better SWB whereas being
obese (b = -5.70, p = 0.035), treated by a medical practi-
tioner (b= -6.35, p = 0.016), and using lifestyle therapies
(b = -6.30, p = 0.010) were predictors of worse SWB. Re-
garding HRQoL, all domains except physical functioning
saw improvement in IP as a statistically significant predictor
for higher HRQoL (Table 6).
Discussion
This study is the first to explore the HRQoL and SWB of
Australian adults with suspected IP. Our results suggest that
altered IP may pose a greater health burden than previously
thought, providing the first indication that Australian adults
with altered IP are susceptible to poor SWB and HRQoL.
Further, several participant characteristics were found to be
associated with the improvement or exacerbation of IP
(Fig. 1).
Increased IP and SWB and HRQoL
Our results suggest that Australian adults with suspected
IP have a lower SWB compared with the Australian popu-
lation. Further, improvement in IP is suggested to be a
significant predictor of SWB and HRQoL. These results
provide the first indication that a relationship between both
SWB and HRQoL and altered IP exists in a diverse range of
health conditions. In support of this relationship, Australian
adults with gastrointestinal disorders (many of which are
associated with altered IP)4 have been found to have a lower
HRQoL compared with Australian adults without gastroin-
testinal disorders.26 Further, a lower QoL has been reported
in diarrhea-predominant irritable bowel syndrome patients
with IP compared with those with a normal intestinal in-
tegrity.27 The association between altered IP and both SWB
and HRQoL contributes to a much needed clinical under-
standing of altered IP, especially as the consequence and
clinical relevance of altered IP in clinical practice have re-
cently been questioned.12 Further, the correlation found
between both SWB and HRQoL and the number of days that
IP affects daily living suggests that the previously reported
symptoms7 and biomarkers5 of altered IP are not the only
clinical consequence of altered IP, with both SWB and
HRQoL now suggested to be involved.
Health care and increased IP
The care provided by health care practitioners compared
with self-care differs not only in the treatments used but
also in the reported outcomes. First, this study identified a
high prevalence of self-prescription of treatment inter-
ventions, primarily dietary products, and lifestyle thera-
pies, for the management of IP. Dietary supplements and
medication were most frequently prescribed by a health
care practitioner. These findings coincide with existing
research that suggests that complementary and integrative
medicine practitioners frequently use dietary supplements
while also using a multimodal and personalized approach
for the management of altered IP.9 Working alongside a
health care practitioner has also been suggested to provide
greater health outcomes compared with no clinic-based
support.28–30 This may explain why in this study Australian
adults who report an improvement in their IP are two times
more likely to be treated by a health care practitioner.
Second, our study found that only 24% of self-treated
participants reported an improvement in their IP compared
with 76% of practitioner-treated participants. These find-
ings suggest that the care provided by health care practi-
tioners to Australian adults with suspected IP may have
beneficial effects on the outcomes of altered IP. Further,
health care practitioners, especially those with limited
experience in the management of altered IP, may draw
on the findings of this study to gain a deeper understand-
ing as to the treatment methods used by Australian adults
with IP.
Features associated with increased IP improvement
Participants who reported an improvement in their IP
were 35% less likely to consume gluten or use NSAIDs. Our
results also found that participants who indicated that they
avoided consuming gluten-containing foods and never used
NSAIDs were associated with a better SWB. These results
concur with clinical studies that show that the consumption
of gluten-containing products and the use of NSAIDs induce
IP.31,32 Practitioners who treat IP also advocate for their
patients with IP to avoid gluten and NSAIDs.9
The finding that vitamin C and vigorous exercise is as-
sociated with improvement of IP conflicts with existing re-
search. First, preliminary research suggests that 500 mg of
vitamin C (ascorbic acid) may induce a rearrangement of the
actin cytoskeleton and thereby an exacerbation of IP.31,33
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Potentially, the association between vitamin C intake and
improvement of IP may be the result of the frequent use in
dietary supplements, especially as participants who reported
an improvement in their IP were 2.7 times more likely to use
dietary supplements. Research has demonstrated a causative
link between vigorous exercise and altered IP.34 As a result
of redistribution of blood flow and splanchnic hypoperfusion
during vigorous exercise, damage to mucosal and epithelial
cells may occur, thereby paving the way for exacerbation of
IP.34 The improvement associated with vigorous exercise in
our study may be the result of improved health; for example,
as health and well-being improve so does the ability to
participate in exercise.35 Further large-scale trials and epi-
demiological research is needed to confirm both of these
hypotheses.
Research agenda
Our study provides useful information where further re-
search can draw on the findings to inform clinical trials and
clinical practice guidelines. The identified characteristics
found to be associated with the improvement and exacerbation
of IP warrant further investigation (Fig. 1). Many of these
associated features are yet to be investigated for their effect on
IP, with clinical research focusing primarily on dietary sup-
plements and dietary products for the treatment of IP.
However, there has been limited investigation exploring
the effectiveness of lifestyle therapies in the management
of IP.9 Nevertheless, many of these lifestyle therapies are
reported to have beneficial health outcomes in health
conditions with a known association with altered IP.36,37
FIG. 1. Participant’s characteristics found to be associated with the improvement and exacerbation of increased intestinal
permeability.
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These results provide a foundation for future clinical trials
where a study exclusively conducted in primary care en-
suring a homogenous study population and standardized
diagnostic criteria may confirm the results of this study.
The findings from this study may also help to inform the
development of a clinical practice guideline for the man-
agement of altered IP. By understanding the treatment
methods used, the development of recommendations can
incorporate the views and preferences of Australian adults
with suspected IP to enable relevant and appropriate rec-
ommendations for this patient group.
Limitations
Although this study involved participants with self-reported
suspected IP, whether there was a confirmed diagnosis of IP is
unknown. However, previous research has shown that people
with self-reported irritable bowel syndrome have similar
health care utilization and QoL as those with diagnosed IBS.38
Many of the health conditions that participants report experi-
encing are known to be more prevalent in females and are
suggested to be associated with IP, which may explain why
93% of participants were female.4 Therefore, these results are
considered relevant to females who suspect they have IP ra-
ther than Australian adults with a confirmed diagnosis of
altered IP. The self-reported outcome of IP has the potential
for recall bias and may not reflect improvement or exacer-
bation of IP. Therefore, to confirm the relationship between
both SWB and HRQoL and altered IP, a clinical study that
measures IP and evaluates both SWB and HRQoL is re-
quired. However, this study provides important and novel
information, advancing the research agenda on the clinical
consequence of altered IP, and suggests potential treatment
strategies that are worth investigating.
Conclusion
The integrity of the small intestine may pose a greater
health burden than previously thought, with susceptibility to
poor SWB and HRQoL reported in Australian adults with
altered IP. Our results strengthen the clinical relevance and
consequence of altered IP, providing the first indication that
a relationship between both SWB and HRQoL and altered
IP exists. Clinical trials may use these findings to further
explore the potential use of the treatment interventions used
by Australian adults with suspected IP.
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